论文部分内容阅读
心血管疾病是糖尿病患者的主要死亡原因,过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptors,PPARs)是核受体超家族中的一个成员,分为PPARα、PPARδ及PPARγ三种类型。PPARα、γ双重激动剂是一类新的药物,与不同的配体结合激活PPARα和PPARγ受体,进而控制糖尿病和具有心血管保护作用。许多研究正在针对PPARα、δ和PPARδ、γ双通道激动剂和PPARα、δ、γ全通道激动剂,研究其对预防糖尿病患者并发心血管疾病的作用。
Cardiovascular disease is the leading cause of death in diabetic patients. Peroxisome proliferator-activated receptors (PPARs), a member of nuclear receptor superfamily, are divided into three types: PPARα, PPARδ and PPARγ Types of. PPARα, γ dual agonist is a new class of drugs that bind to different ligands to activate PPARα and PPARγ receptors, thereby controlling diabetes and having cardiovascular protective effect. Many studies are looking at PPARα, δ and PPARδ, γ dual-channel agonists and PPARα, δ, γ full-channel agonists to study their role in the prevention of cardiovascular disease in patients with diabetes.